AngioDynamics (NASDAQ:ANGO) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

AngioDynamics (NASDAQ:ANGO - Get Free Report) announced its quarterly earnings results on Wednesday. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07, RTT News reports. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company's revenue was down .1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.05) EPS. AngioDynamics updated its FY 2025 guidance to -0.380--0.340 EPS and its FY25 guidance to ($0.38)-($0.34) EPS.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO traded up $3.54 during mid-day trading on Wednesday, hitting $12.94. 4,421,281 shares of the stock traded hands, compared to its average volume of 1,328,826. The stock has a fifty day moving average price of $7.87 and a 200-day moving average price of $7.30. The company has a market cap of $525.80 million, a price-to-earnings ratio of -2.12 and a beta of 0.59. AngioDynamics has a 52 week low of $5.26 and a 52 week high of $13.13.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ANGO shares. Canaccord Genuity Group cut their target price on AngioDynamics from $13.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, October 4th. HC Wainwright reissued a "buy" rating and set a $14.00 target price on shares of AngioDynamics in a research note on Tuesday, December 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.